GoConnect Limited

GoConnect Limited (NSX:GO8) holds 43.5% of Go Green Holdings Ltd which holds a major interest of 24% in COVIRIX Medical. The proposed merger values COVIRIX Medical at US$617 million.

GoConnect Ltd (NSX:GO8) holds 43.5% of Go Green Holdings Ltd which holds a major interest of 24% in COVIRIX Medical. The proposed merger values COVIRIX Medical at US$617 million which, when consummated, will involve NIVF issuing its shares at a deemed price of US$6 per share.

GoConnect Limited (NSX:GO8) advise that COVIRIX Medical and Numolux Group have entered into a strategic partnership for anti-viral drug development platform.

The Directors of GoConnect Limited (NSX:GO8) provide the following report for the quarter ended 30 June 2023.

GoConnect Limited (NSX:GO8) is pleased to advise that COVIRIX Medical Pty Ltd, of which Go Green Holdings Ltd has a 24% interest, has been granted a 20 years patent by IP Australia for the company's repurposed antiviral treatment and prevention of pulmonary infections.

GoConnect Limited (NSX:GO8) continued to derive income from sale of investment. However, in the June 2022 quarter, GO8 withheld further sale pending the generation of revenue from a number of investments held by Go Green Holdings Ltd.

GoConnect Limited (NSX:GO8) is pleased to provide a copy of media release received from COVIRIX Medical and US DiaCarta Inc in respect of the establishment of their global partnership.

GoConnect Limited (NSX:GO8) is pleased to provide a copy of an investment research report on COVIRIX Medical Holdings Ltd prepared by Pitt Street Research ("PSR") and distributed by Martin Place Securities.

GoConnect Limited's (NSX:GO8) primary corporate objective is to establish the Company as a strategic investor in a number of businesses that will contribute to the health of the global environment and health of humanity.

GoConnect Limited (NSX:GO8) is pleased to report on successful virology test results recently received by COVIRIX Medical Pty Ltd against the Delta strain of SARS CoV-2.